DE602004031221D1 - Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung - Google Patents

Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung

Info

Publication number
DE602004031221D1
DE602004031221D1 DE602004031221T DE602004031221T DE602004031221D1 DE 602004031221 D1 DE602004031221 D1 DE 602004031221D1 DE 602004031221 T DE602004031221 T DE 602004031221T DE 602004031221 T DE602004031221 T DE 602004031221T DE 602004031221 D1 DE602004031221 D1 DE 602004031221D1
Authority
DE
Germany
Prior art keywords
preparation
tetrahydrocannabinol
delta
cannabinoid derivatives
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031221T
Other languages
German (de)
English (en)
Inventor
Bob M Moore
Antonio M Ferreira
Mathangi Krishnamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of DE602004031221D1 publication Critical patent/DE602004031221D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004031221T 2003-05-20 2004-05-20 Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung Expired - Lifetime DE602004031221D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47231603P 2003-05-20 2003-05-20
PCT/US2004/015885 WO2004113320A1 (en) 2003-05-20 2004-05-20 Cannabinoid derivatives, methods of making, and use thereof

Publications (1)

Publication Number Publication Date
DE602004031221D1 true DE602004031221D1 (de) 2011-03-10

Family

ID=33539041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031221T Expired - Lifetime DE602004031221D1 (de) 2003-05-20 2004-05-20 Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung

Country Status (10)

Country Link
US (2) US7169942B2 (https=)
EP (1) EP1633733B1 (https=)
JP (1) JP2007501279A (https=)
CN (1) CN1809552A (https=)
AT (1) ATE496901T1 (https=)
AU (1) AU2004249669B2 (https=)
CA (1) CA2526103A1 (https=)
DE (1) DE602004031221D1 (https=)
DK (1) DK1633733T3 (https=)
WO (1) WO2004113320A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1727900A4 (en) * 2004-03-26 2008-05-28 Fujifilm Corp METHOD FOR SELECTIVELY SEPARATING AND CLEANING RNA, AND METHOD FOR SEPARATING AND CLEANING NUCLEIC ACID
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
USRE46558E1 (en) 2005-04-28 2017-09-26 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
CA2623723A1 (en) 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
DE102005062098A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Oxaphenanthren-Derivate
JP2009528381A (ja) * 2006-02-28 2009-08-06 パロマ ファーマシューティカルズ，インク． 細胞増殖および血管新生を特徴とする疾患を治療する組成物および方法
CN101668425A (zh) 2007-03-02 2010-03-10 田纳西州立大学研究基金会 三芳基/杂芳族大麻素类和其应用
US20110021618A1 (en) * 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US8476439B2 (en) 2008-05-19 2013-07-02 The University Of Tennessee Research Foundation Pyridine classical cannabinoid compounds and related methods of use
US8389534B2 (en) * 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
US8541431B2 (en) * 2008-05-19 2013-09-24 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
JP2011520974A (ja) * 2008-05-19 2011-07-21 ユニヴァーシティ オブ テネシー リサーチ ファウンデーション，ザ ピリミジンの古典的カンナビノイド化合物及び関連する使用方法
CA2724697A1 (en) * 2008-05-19 2009-11-26 University Of Tennessee Research Foundation, The Pyridine classical cannabinoid compounds and related methods of use
US8349876B2 (en) 2008-05-19 2013-01-08 The University Of Tennesee Research Foundation Pyridine non-classical cannabinoid compounds and related methods of use
US8158654B2 (en) 2008-05-19 2012-04-17 The University Of Tennessee Research Foundation Pyridine non-classical cannabinoid compounds and related methods of use
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
US10059683B2 (en) * 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US20180169061A1 (en) * 2016-12-15 2018-06-21 Ascent Pharmaceuticals, Inc. Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
AU2018323861B2 (en) * 2017-08-27 2023-08-17 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
JP2021535203A (ja) 2018-08-20 2021-12-16 ベッソール ファルマ、エルエルシー 既知および新規カンナビノイドの適用
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
CN110269839A (zh) * 2019-06-15 2019-09-24 云南飞久逍科技有限公司 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用
CA3156487A1 (en) * 2019-10-03 2021-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. LIPOSOMAL CANNABINOIDS AND ASSOCIATED USES
IL292775A (en) 2019-11-08 2022-07-01 Vella Bioscience Inc preparations containing cannabidiol (cbd) that act peripherally and their use to improve female sexual function or to treat female sexual disorders
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941782A (en) * 1972-04-27 1976-03-02 Sharps Associates Heterocyclic esters of benzopyrans
US3915996A (en) * 1972-10-16 1975-10-28 Abbott Lab Process for making benzopyrans
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
DE4100441A1 (de) * 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
DE69822449T2 (de) 1997-01-21 2005-01-27 Smithkline Beecham Corp. Neue cannabinoidrezeptor-modulatoren
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
US5948777A (en) 1997-03-18 1999-09-07 Smithkline Beecham Corporation Cannabinoid receptor agonists
US5939429A (en) 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
WO2001003690A1 (en) 1999-07-12 2001-01-18 Virginia Commonwealth University Novel vasodilator cannabinoid analogs
FR2799124B1 (fr) 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
FR2804604B1 (fr) 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US20040039048A1 (en) 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
DE60125541T2 (de) * 2000-06-22 2007-10-11 Pharmos Corp. Neue nicht psychotropische cannabinoide
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
CN100567266C (zh) 2001-11-14 2009-12-09 先灵公司 类大麻苷受体配体
DE60319714T2 (de) 2002-06-19 2009-04-02 Schering Corp. Agonisten des cannabinoidrezeptors
US20040077650A1 (en) 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
AU2004249669B2 (en) 2008-05-22
AU2004249669A1 (en) 2004-12-29
US20040242593A1 (en) 2004-12-02
EP1633733A4 (en) 2007-02-28
DK1633733T3 (da) 2011-05-16
CN1809552A (zh) 2006-07-26
US7169942B2 (en) 2007-01-30
ATE496901T1 (de) 2011-02-15
CA2526103A1 (en) 2004-12-29
US20070167514A1 (en) 2007-07-19
JP2007501279A (ja) 2007-01-25
EP1633733A1 (en) 2006-03-15
WO2004113320A1 (en) 2004-12-29
EP1633733B1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
DE602004031221D1 (de) Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
NO20010446L (no) Substituert anilidforbindelser og metoder
DE69422191D1 (de) A1 adenosin rezeptor agonisten und antagonisten
CO5450244A1 (es) Derivados de adenina
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
DE69728585D1 (de) Mittel gegen Juckreiz
BR0015962A (pt) Compostos tendo ligações multiplas que são agonistas de receptor adrenérgico (beta)2 úteis no tratamento e prevenção de doenças respiratórias
BR9707136A (pt) Derivados morfinóides condesados em heterociclo (ii)
NO20003550L (no) Farmasøytiske sammensetninger og anvendelse herav
ATE338565T1 (de) Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm)
ATE144773T1 (de) Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
DE69626705D1 (de) A1 adenosin rezeptor agonisten und antagonisten
ATE365165T1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
PT901374E (pt) Tetra-hidropteridinas e piridilpiperazinas para o tratamento de disturbios neurologicos
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
AU5614198A (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
DE60103856D1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
BR0307903A (pt) derivados de arilsulfona
BR0015540A (pt) Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
DE50209113D1 (de) 1-allyl-ergotalkaloid-derivate- verfahren zu ihrer herstellung und ihre verwendung zur prophylaxe und therapie von migräne
Feuerstein et al. Endogenous agonists may change the concentration-response curves of exogenous agonists: source of quantitative information about the endogenous tone
BR0307584A (pt) Pirimidinonas e pirimidinationas substituìdas